Targeting microRNAs for metabolic disorders
Described herein are compounds comprising modified oligonucleotides that are complementary to miR-103 and/or miR-107 and methods of treating diseases and disorders using the compounds.
1. A compound comprising the structure:
wherein X is a phosphodiester linkage; each N of N m is a deoxyadenosine (A); m is 2; Y is a phosphodiester linkage; and MO is 5′-C S A S A S U S G S C S U S G S C S A S AAC S A S A S U S G S C S U S G S C S A S -3′ (SEQ ID NO: 7), wherein each nucleoside followed by a subscript “S” is a S-cEt nucleoside, each nucleoside not followed by a subscript is a deoxynucleoside, and each internucleoside linkage between two S-cEt nucleosides is a phosphorothioate linkage, and the remaining internucleoside linkages are phosphodiester linkages; and wherein Y is linked to the 3′ terminus of MO; or a pharmaceutically acceptable salt thereof.
2. A compound having the structure:
3. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
4. The pharmaceutical composition of claim 3 , which is an aqueous composition.
5. The pharmaceutical composition of claim 3 , which is a lyophilized composition.
6. A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier.
7. The pharmaceutical composition of claim 6 , which is an aqueous composition.
8. The pharmaceutical composition of claim 6 , which is a lyophilized composition.